VS-6063 significantly decreased tumor growth and the expression of the above ESCC tumor biomarkers, especially in the presence of TAMs, indicating that the FAK inhibitor exhibited a stronger antitumor effect in TAM-coinjected ESCC tumors than in non-TAM-coinjected ESCC tumors (Fig. S5A–S5C). This evidence concerns the gene PTK2 and neoplasm.